Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer
BJU International · 2025
DOI: 10.1111/bju.16509 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift BJU International, 2025. Verfasst von Jacob I Taylor und 23 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: BCG Vaccine, Cystectomy, Non-Muscle Invasive Bladder Neoplasms, Organ Sparing Treatments. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To quantify the oncological risks of bladder‐sparing therapy (BST) in patients with Bacillus Calmette–Guérin (BCG)‐unresponsive non‐muscle‐invasive bladder cancer (NMIBC) compared to upfront radical cystectomy (RC). Patients and Methods Pre‐specified data elements were collected from retrospective cohorts of patients with BCG‐unresponsive NMIBC from 10 international sites. After Institutional Review Board approval, patients were included if they had BCG‐unresponsive NMIBC meeting United States Food and Drug Administration criteria. Oncological outcomes were collected following upfront RC or BST. BST regimens included re‐resection or surveillance only, repeat BCG, intravesical chemotherapy, systemic immunotherapy, and clinical trials.
Results
Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow‐up was 50 (20–69) months. There were no statistically significant differences in metastasis‐free survival, cancer‐specific survival, or overall survival between treatment groups. In the BST group, high‐grade recurrence rates were 37% and 52% at 12 and 24 months and progression to MIBC was observed in 7% and 13% at 12 and 24 months, respectively. RC was performed in 31.7% in the BST group and nodal disease was found in 13% compared with 4% in upfront RC ( P = 0.030).
Conclusion
In a selected cohort of patients, initial BST offers comparable survival outcomes to upfront RC in the intermediate term. Rates of recurrence and progression increase over time especially in patients treated with additional lines of BST.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Texas Southwestern Medical Center, Dallas, TX, USA.
- University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- University of Iowa, Iowa City, IA, USA.
- Moffit Cancer Center, Tampa, FL, USA.
- Brigham and Women's Hospital, Boston, MA, USA.
- Penn State Health, Hershey, PA, USA.
ORCID-Profile: Jacob I Taylor, Michael A O'Donnell, Jeffrey Howard, Ian McElree, Mathieu Roumiguié, Roger Li, Yair Lotan
Zitieren
APA
Taylor, J. I., Kamat, A. M., O'Donnell, M. A., Annapureddy, D., Howard, J., Tan, W. S., McElree, I., Davaro, F., Yim, K., Harrington, S., Dyer, E., Black, A. J., Kanabur, P., Roumiguié, M., Lerner, S., Black, P. C., Raman, J. D., Preston, M. A., Steinberg, G., …, & Lotan, Y. (2025). Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer. BJU International. https://doi.org/10.1111/bju.16509
Vancouver
Taylor JI, Kamat AM, O'Donnell MA, Annapureddy D, Howard J, Tan WS, et al. Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer. BJU International. 2025. doi:10.1111/bju.16509
BibTeX
@article{Taylor2025,
author = {Taylor, Jacob I and Kamat, Ashish M and O'Donnell, Michael A and Annapureddy, Drupad and Howard, Jeffrey and Tan, Wei Shen and McElree, Ian and Davaro, Facundo and Yim, Kendrick and Harrington, Stephen and Dyer, Elizabeth and Black, Anna J and Kanabur, Pratik and Roumiguié, Mathieu and Lerner, Seth and Black, Peter C and Raman, Jay D and Preston, Mark A and Steinberg, Gary and Huang, William and Li, Roger and Packiam, Vignesh T and Woldu, Solomon L and Lotan, Yair},
title = {Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer},
journal = {BJU International},
year = {2025},
doi = {10.1111/bju.16509}
}
EUVIMED